Clinical Trial Update: Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of denosumab in pediatric patients with glucocorticoid-induced osteoporosis. Results were posted in July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucocorticoid-induced Osteoporosis

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Amgen | Conditions: Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2024-07-19